ArticleWorld journal of gastrointestinal oncology2025
Untargeted metabolomics analysis of metabolite changes in gastric cancer patients from plateau regions.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbial dynamics in gastric cancer: insights from full-length 16S rRNA nanopore sequencing in the MAGIC cohort.Frontiers in microbiology · 2026Article
- The Rare RNA Methylations m²G, Cm, m⁵U and ms²i⁶A: Roles in Disease Pathogenesis and Emerging Therapeutic Implications.International journal of medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolomics sequencing technology was used to investigate the changes of intestinal flora and metabolites in gastric cancer patients in plateau areas.
aimTo investigate changes in gut microbiota and their metabolites in patients with gastric cancer from plateau regions using untargeted metabolomic sequencing.
methodsFresh morning fecal samples were collected from 30 gastric cancer patients diagnosed at a tertiary hospital in Qinghai Province and 30 healthy individuals (controls). Liquid chromatography-tandem mass spectrometry based untargeted metabolomic sequencing was used to analyze metabolite changes and predict metabolic function.
resultsMetabolomic analysis identified 281 metabolites in samples from both groups. These metabolites were categorized into eight major classes, listed in descending order of abundance: Lipids and lipid-like molecules (35.443%); organic acids and derivatives (29.114%); organic oxygen compounds (15.19%); nucleosides, nucleotides, and analogs (13.924%); organoheterocyclic compounds (2.532%), amino acids and peptides (1.266%); benzenoids (1.266%); and fatty acids (1.266%). Compared with the control group, the top 10 metabolites elevated in the gastric cancer group included: Dethiobiotin, glycylproline, glycine, hydroxyisocaproic acid, tyramine, methionine sulfoxide, 5-aminopentanoic acid, citrulline, betonicine, and formiminoglutamic acid and the top 10 decreased were: Cytidine, 5'-methylthioadenosine, trehalose, melibiose, lotaustralin, adenosine, inosine, ribothymidine, raffinose, and galactinol. Functional prediction analysis revealed that these differential metabolites were primarily enriched in 12 metabolic pathways, including purine metabolism, cysteine and methionine metabolism, galactose metabolism, lysine degradation, glycine, serine, and threonine metabolism, biotin metabolism, pyrimidine metabolism, arginine and proline metabolism, histidine metabolism, primary bile acid biosynthesis, starch and sucrose metabolism, and tyrosine metabolism.
conclusionSignificant differences in intestinal microbial metabolites and associated metabolic pathways were observed between gastric cancer patients and healthy controls residing in plateau regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.